Work

P3.12.42 Concurrent KRAS Mutations Render Single-Agent EGFR Inhibitors Futile in Advanced NSCLC

Year: 2025

Type: article

Source: Journal of Thoracic Oncology

DOI: 10.1016/j.jtho.2025.09.904

Authors: I. Aza, M. Nagasaka, A. Azmi, T. Al Baghdadi, E. Dib, F. Abu-Rous, A. Qin, R. Shah, N. Vojjala, K. Goyal, G. Li, J. Quintanilha, J. Altenburg, R. Graf

Institutions: Wayne State University, University of California, Irvine, The Barbara Ann Karmanos Cancer Institute, Trinity Health Ann Arbor Hospital, Henry Ford Health, Henry Ford Hospital, University of Michigan, U-M Rogel Cancer Center, Foundation Medicine (United States)

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4415519844

FWCI:

Cites:

Cited by:

Related to: